FCMI
Foresite Capital Management II Portfolio holdings
AUM
$29.2M
This Quarter Return
+5.43%
1 Year Return
+44.84%
3 Year Return
-66.21%
5 Year Return
-37.37%
10 Year Return
–
AUM
$284M
AUM Growth
+$284M
(-1%)
Cap. Flow
-$10.9M
Cap. Flow
% of AUM
-3.86%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
1
Increased
3
Reduced
2
Closed
1
Top Buys
| 1 |
ADAP
Adaptimmune Therapeutics
ADAP
|
$3.56M |
| 2 |
AIMT
Aimmune Therapeutics, Inc.
AIMT
|
$990K |
| 3 |
Sangamo Therapeutics
SGMO
|
$488K |
| 4 |
BDSI
BioDelivery Sciences International, Inc.
BDSI
|
$90K |
Top Sells
| 1 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$14M |
| 2 |
EPZM
Epizyme, Inc
EPZM
|
$1.22M |
| 3 |
Ardelyx
ARDX
|
$808K |
Sector Composition
| 1 | Healthcare | 33.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AERI
1
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $98.9M | 34.86% | 1,464,749 -207,965 | -12% | -$14M |
|
|
AIMT
2
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $90.3M | 31.8% | 3,356,749 +36,804 | +1% | +$990K |
|
|
ALDR
3
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $26.6M | 9.39% | 1,686,220 | – | – |
|
4
Insmed
INSM
$28.8B
| $22.9M | 8.06% | 967,636 | – | – |
|
|
EPZM
5
DELISTED
Epizyme, Inc
EPZM
| $19.9M | 7.01% | 1,468,215 -89,893 | -6% | -$1.22M |
|
|
XLRN
6
DELISTED
Acceleron Pharma Inc.
XLRN
| $11.9M | 4.18% | 244,756 | – | – |
|
|
ADAP
7
Adaptimmune Therapeutics
ADAP
$15.6M
| $8.31M | 2.93% | 700,000 +300,000 | +75% | +$3.56M |
|
8
Denali Therapeutics
DNLI
$2.23B
| $3.81M | 1.34% | 250,000 | – | – |
|
|
9
Sangamo Therapeutics
SGMO
$157M
| $1.14M | 0.4% | 80,500 +34,362 | +74% | +$488K |
|
|
BDSI
10
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $90K | 0.03% | +30,500 | New | +$90K |
|
|
11
Ardelyx
ARDX
$1.53B
| – | – | -159,967 | Closed | -$808K |
|